Clinical Trial Update: The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the efficacy and safety of F520 in patients with relapsed/refractory Peripheral T Cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• F520

Snippet

Sponsor: Shandong New Time Pharmaceutical Co., LTD | Conditions: Peripheral T Cell Lymphoma | Phase 2 | Status: UNKNOWN